- Title
- Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society
- Creator
- Lyon, Alexander R.; Dent, Susan; Stanway, Susannah; Earl, Helena; Brezden-Masley, Christine; Cohen-Solal, Alain; Tocchetti, Carlo G.; Moslehi, Javid J.; Groarke, John D.; Bergler-Klein, Jutta; Khoo, Vincent; Tan, Li Ling; Anker, Markus S.; von Haehling, Stephan; Maack, Christoph; Pudil, Radek; Barac, Ana; Thavendiranathan, Paaladinesh; Ky, Bonnie; Neilan, Tomas G.; Sverdlov, Aaron L.
- Relation
- European Journal of Heart Failure Vol. 22, Issue 11, p. 1945-1960
- Publisher Link
- http://dx.doi.org/10.1002/ejhf.1920
- Publisher
- John Wiley & Sons
- Resource Type
- journal article
- Date
- 2020
- Description
- This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
- Subject
- risk factors; cardio-oncology; cardiotoxicity; heart failure; risk prediction; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1453126
- Identifier
- uon:44599
- Identifier
- ISSN:1388-9842
- Rights
- © 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
- Language
- eng
- Full Text
- Reviewed
- Hits: 6654
- Visitors: 6727
- Downloads: 112
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 669 KB | Adobe Acrobat PDF | View Details Download |